CAMBRIDGE, Mass., Feb. 15 /PRNewswire-FirstCall/ -- Transkaryotic
Therapies, Inc. (Nasdaq: TKTX) today announced that Tamara L. Joseph has
joined the company as Vice President, General Counsel. Ms. Joseph has broad
legal experience in the pharmaceutical industry, including 16 years of
experience in the US, France and Belgium. She joins TKT from Biogen Idec
where she served as Vice President, International Legal. In her role as
General Counsel at TKT, Ms. Joseph will have responsibility for all its legal
and government relations activities.
"I am confident that Tamara's knowledge, judgment and integrity will be
important assets for TKT," said Michael J. Astrue, President and Chief
Executive Officer. "In addition, her broad experience within the
pharmaceutical industry will be extremely beneficial to us as we continue to
bring new products to market over the next several years."
While at Biogen Idec, Ms. Joseph had overall responsibility for the
international legal and public affairs functions, advising senior management
on international legal issues. She was also an Associate at the law offices
of Morrison & Foerster in New York, Los Angeles and Brussels, where she
handled litigation, intellectual property, and commercial law matters. Prior
to joining Morrison & Foerster, Ms. Joseph was an Associate at Fried, Frank,
Harris, Shriver & Jacobson in New York. She received a B.A. from Duke
University, a J.D. from the University of Michigan Law School, and LLM degrees
from the College of Europe and from the University of Paris. She is admitted
to practice law in New York, California, England and Wales.
Transkaryotic Therapies, Inc. is a biopharmaceutical company primarily
focused on researching, developing and commercializing treatments for rare
diseases caused by protein deficiencies. Within this focus, the company
markets Replagal(TM), an enzyme replacement therapy for Fabry disease, and is
developing treatments for Hunter syndrome and Gaucher disease. In addition to
its focus on rare diseases, TKT intends to commercialize Dynepo(TM), its Gene-
Activated(R) erythropoietin product for anemia related to kidney disease, in
the European Union. TKT was founded in 1988 and is headquartered in
Cambridge, Massachusetts, with additional operations in Europe, Canada and
South America. Additional information about TKT is available on the company's
website at http://www.tktx.com.
This press release contains forward-looking statements regarding TKT's
management structure, as well as statements containing the words "believes,"
"anticipates," "plans," "expects," "estimates," "intends," "should," "could,"
"will," "may," and similar expressions. There are a number of important
factors that could cause the company's actual results to differ materially
from those indicated by such forward-looking statements, including, whether
TKT will be able to successfully manage its legal and business development
functions, and other factors set forth under the caption "Certain Factors
Which May Affect Future Results" in the company's Quarterly Report on Form 10-
Q for the quarter ended September 30, 2004, which is on file with the
Securities and Exchange Commission and are incorporated herein by reference.
While the company may elect to update forward-looking statements at some point
in the future, the company specifically disclaims any obligation to do so,
even if its expectations change.
Gene-Activated(R) is a registered trademark and Replagal(TM) is a
trademark of Transkaryotic Therapies, Inc. Dynepo(TM) is a trademark of
Sanofi-Aventis SA.
For More Information Contact:
Justine E. Koenigsberg
Senior Director, Corporate Communications
(617) 349-0271
Daniella M. Lutz
Corporate Communications Manager
(617) 349-0205
SOURCE Transkaryotic Therapies, Inc.
 back to top
Related links:
http://www.tktx.com
Photo Notes:
NewsCom:
http://www.newscom.com/cgi-bin/prnh/19990913/TKTLOGO
AP Archive: http://photoarchive.ap.org
PRN Photo Desk, photodesk@prnewswire.com
Company News On-Call:
http://www.prnewswire.com/comp/120657.html
CONTACT:
Justine E. Koenigsberg, Senior Director,
Corporate Communications, +1-617-349-0271, or Daniella M. Lutz,
Corporate Communications Manager, +1-617-349-0205 both of
Transkaryotic Therapies, Inc.
|
